Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 5,280 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 5,280 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $51.66, for a total value of $272,764.80. Following the sale, the chief executive officer owned 90,920 shares of the company’s stock, valued at approximately $4,696,927.20. This represents a 5.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total value of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.68, for a total value of $556,300.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total value of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total value of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.37, for a total value of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.42, for a total value of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total value of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $52.38 on Friday. The company’s fifty day moving average is $47.34 and its 200-day moving average is $42.65. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $56.30. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 0.80 and a beta of 0.74. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Equities analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be given a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. Phibro Animal Health’s payout ratio is currently 21.33%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after buying an additional 546 shares during the period. Millennium Management LLC grew its position in Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares in the last quarter. Jane Street Group LLC increased its stake in Phibro Animal Health by 65.3% during the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after acquiring an additional 13,404 shares during the period. Envestnet Asset Management Inc. raised its holdings in Phibro Animal Health by 97.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock valued at $621,000 after acquiring an additional 11,999 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Phibro Animal Health by 0.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 268,877 shares of the company’s stock valued at $6,867,000 after acquiring an additional 906 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Wall Street Analysts Forecast Growth

PAHC has been the topic of a number of analyst reports. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a report on Friday, February 6th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.